Platelet count >= ,/ul Platelet count >= ,/uL Platelet count >=,/ul Platelet count >= ,/ul; for patients with >= % plasma cell involvement of the bone marrow, platelet count >= ,/ul is acceptable Platelet count >= ,/ul (>= , per mm^) must be met within days of CD Platelet count of >= ,/uL Platelet count > ,/uL Platelet count >= ,/uL, within days of registration Platelet count >= ,/uL Platelet count ? ,/uL Platelet count < ,/uL without full-dose anticogulation therapy Platelet count < ,/uL with ongoing full-dose anticoagulation therapy Platelet count >= K/uL within days prior to start of protocol therapy. Platelet count > ,/uL PHASE I: Platelet count >= ,/uL PHASE IB: Platelet count >= ,/uL Platelet count of >= ,/uL Platelet count < ,/uL Platelet count > ,/ul within four weeks of enrollment Platelet count >= , K/uL Platelet count >= ,/?l (except in hepatocellular carcinoma patients with portal hypertension for whom a platelet count > ,/ul is allowed) Platelet count >= ,/uL Platelet count >= ,/uL. TREATMENT WITH SJCAR: Platelet count > ,/uL (can be transfused) Platelet count < ,/uL Within days prior to treatment start: Platelet count >= ,/ul Platelet count >= ,/uL Platelet >= ,/uL Platelet count >= ,/uL Platelet count >= x ^/L (>= , /uL) Platelet count =< , x ^/uL at the screening visit Platelet count >= , cells/uL Platelet count > K/uL Platelet count >= ,/uL Platelet count > ,/uL unless disease-related (due to marrow infiltration or splenomegaly) Platelet count of >= ,/uL Platelet count >= ,/uL Platelet count < ,/uL Platelet count >= ,/uL Platelet count < K/uL Platelet count > ,/uL Platelet count >= ,/uL Platelet count >= ,/uL prior to biopsy; platelets >= ,/uL prior to infusion Platelet count >= ,/uL Within days prior to the first study treatment (cycle , day ): Platelet count >= ,/uL; for patients with hematologic malignancies, platelet count >= ,/uL Platelet count >= ,/uL; for patients with hematologic malignancies, platelet count >= ,/uL Platelet ? ,/uL Platelet count ?,/uL Within days of registration: Platelet count >= ,/ul Platelet count >= ,/ul prior to biopsy; platelet count >= ,/ul prior to infusion Platelet count >= ,/uL Platelet count >= , cells/uL Platelet count >= ,/uL Platelet count of >= ,/uL Platelet count of >= ,/ul Platelet count >= ,/uL within days prior to CD Platelet count >= ,/uL Platelet count > K/uL Platelet count >= , platelets/ul Platelet count >= ,/uL Platelet count < ,/uL Platelet count >= ,/uL ARM A COHORT : Platelet count >= ,/ul ARM B COHORT : Platelet count >= ,/ul ARM B COHORT : Platelet count >= ,/ul ARM C COHORT : Platelet count >= ,/ul Platelet count >= ,/uL Must be met within days of CD: Platelet count >= ,/ul Platelet >= ,/uL Platelet count >= ,/uL Platelet count >= ,/uL Platelet count >= ,/uL Platelet count >= , cells/uL Platelet count >= ,/ul (phase I only) Platelet count >= ,/uL Platelet count >= x ^ /uL without platelet transfusions Platelet count >= ,/ul Platelet count >= ,/ul Platelet count >= K/uL (in the expansion cohorts, if thrombocytopenia is due to bone marrow involvement platelet count must be >= K/uL), without platelet transfusions for week Platelet count < ,/ul Platelet > ,/uL Platelet count > ,/uL during screening evaluation Platelet count >= , cells/ul Within days prior to the first study treatment (cycle , day ): Platelet count >= ,uL for patients with hematologic malignancies, platelet count >= ,/uL. Platelet count >/= , platelets/ul prior to initial treatment Platelet count >= ,/uL Platelet count >= ,/ul Platelet count >= ,/uL Platelet count >= ,/uL Platelet count >= ,/uL Platelet count >= ,/uL Platelet count >= ,/ul Platelet >= ,/uL Platelet count >= ,/uL Platelet count >= ,/uL; for patients with hematologic malignancies, platelet count >= ,/uL Platelet count >= , cells/uL Platelet count > ,/ul Patients must have a platelet count >= ,/uL at the time of the initial evaluation Platelet count of greater than ,/uL Platelet count >= ,/uL Platelet count >= ,/uL Platelet count >= ,/ul Platelet count > ,/ul Platelet count >= ,/UL Platelet count >= ,/uL Platelet >= ,/uL Platelet count >= ,/uL Platelet count >= ,/uL Platelet count >= ,ul Platelet ? , / uL Platelet count >= ,/uL Platelet count > ,/uL Platelet count (untransfused) >= ,/uL Platelet count > ,/uL Platelet count > K/uL Presence of significant active bleeding or condition requiring maintenance of a platelet count > ,/uL Platelet count >= ,/uL Platelet count > ,/uL or > ,/uL if bone marrow (BM) involvement or splenomegaly Within days prior to the first study treatment (cycle , day ): Platelet count >= ,/uL; for patients with hematologic malignancies, platelet count >= ,/uL Platelet count > ,/ul Platelet count >= ,/uL Platelet count >= K/u (in the Phase IIa portion, if thrombocytopenia is due to bone marrow involvement platelet count must be >= K/uL) Platelet count >= ,/uL Platelet count >= , cells/uL Platelet count >= ,/uL Platelet count >= ,/ul Platelet count < ,/uL The platelet count must be at least ,/uL Platelet count >= x ^/uL Untransfused platelet count >= ,/uL Platelet count >= ,/uL Thrombocytopenia (platelet count < x ^/uL) Platelet count >= ,/uL Platelet count of less than ,/uL Platelet count =< ,/uL Platelet count >= K/uL, if thrombocytopenia is due to bone marrow involvement platelet count must be >= K/uL Platelet count >= ,/ul Platelet count >= ,/ul Platelet count >= ,/ul prior to biopsy; platelets >= ,/ul prior to infusion Platelet count >= ,/uL Platelet count >= ,/uL Platelet count >= ,/ul Platelet count > ,/ul Platelet count >= ,/uL Platelet count of > ,/ul Platelet count >= ,/ul Thrombocytopenia (platelet count < x ^/uL) Platelet count must be >= ,/uL Platelet count >= ,/uL Platelet count >= ,/ul Platelet count ? ,/uL Platelet count > ,/ ul Platelet count >= ,/uL Platelet >= ,/uL Platelet count >= ,/ul Platelet count >= ,/ul Platelet >= ,/uL Platelet count >= ,/uL (Untransfused) platelet count >= /uL Untransfused platelet count >= /uL Platelet count > /uL Platelet count >= ,/uL Platelet count >= ,/uL Platelet count of >= ,/uL Platelet count < ,/uL Platelet count >= ,/ul (corrected if needed) Platelet count >= ,/uL Platelet count >= ,/uL Platelet count >= ,/uL Platelet count > ,/uL Platelet count > ,/ul Platelet count: -/uL Stable platelet count >= ,/mm^ (>= k/uL) Platelet count >= ,/ul Platelet count of =< ,/uL Existing major organ dysfunction > grade , with the exception of myelosuppression (neutrophil count >= /ul and platelet count >= ,/ul are acceptable) and hearing loss Platelet count has to be >= ,/uL in patients undergoing biopsy Platelet count >= ,/uL Unacceptable hemogram: platelet count < ,/ul Platelet > ,/uL Platelet count > /uL